Hormone Therapy for Men: How It Works and What to Expect
Introduction: The Gap Between How Men Feel and the Care They Receive
An estimated 35% of men over age 45 have clinically low testosterone, a condition known as hypogonadism. Yet only about 5% of hypogonadal men currently receive any treatment. That is a wide gap, and most men sitting inside it never get a clear explanation for why they feel the way they do.
The symptoms are familiar: persistent fatigue, gradual weight gain, low libido, mood changes, disrupted sleep, and cognitive fog. These are often dismissed as the inevitable cost of getting older. In many cases, they are not inevitable at all. They are signals, and some of them are addressable.
It is also worth being precise about what hormone therapy actually is. It is not simply a testosterone prescription handed across a counter. Done well, it is a clinically structured, metabolically integrated program that depends on proper diagnosis, ongoing oversight, and lifestyle integration to produce meaningful, lasting results.
This matters more now than it has in years. The period spanning 2025 and 2026 brought landmark changes to how testosterone therapy is classified and labeled, making this a useful moment for men to understand their options with accurate, current information.
What Is Hormone Therapy for Men?
In clinical terms, hormone therapy for men is a medically supervised program designed to restore testosterone and related hormones to optimal physiological ranges in men with confirmed deficiency.
Testosterone replacement therapy (TRT) is the most common intervention, but the broader framework often assesses other biomarkers as well, including DHEA, thyroid function, and cortisol. The goal is to understand how the whole system is functioning, not to chase a single number.
Hypogonadism comes in two forms. Primary hypogonadism originates in the testes. Secondary hypogonadism originates in the pituitary gland or hypothalamus. There is also late-onset hypogonadism, which is increasingly linked to obesity, metabolic syndrome, and sleep apnea rather than classical disease alone.
Testosterone declines roughly 1% per year after age 30, and more than 60% of men over age 65 have free testosterone below the normal values of men aged 30 to 35. Hormone optimization is best treated as a tool for restoring how the body functions, not as a standalone fix or a cosmetic intervention.
Who Is a Candidate? Understanding Prevalence and Risk Factors
The landmark HIM Study found a crude hypogonadism prevalence of 38.7% in men aged 45 and older in U.S. primary care, with risk increasing 17% per decade of age.
Metabolic health is closely tied to hormonal health. The same research showed significantly elevated odds in men with obesity (2.38x), type 2 diabetes (2.09x), and hypertension (1.84x).
Men in their 40s deserve specific mention. Prevalence of late-onset testosterone deficiency in this group is estimated at 6 to 12%, often driven by lifestyle-related metabolic conditions rather than aging alone.
The major modifiable contributors are obesity, sedentary behavior, sleep apnea, and chronic stress. These should be evaluated and addressed as part of any responsible program. Candidacy is determined by confirmed biochemical deficiency plus symptoms, not symptoms alone. That standard is what separates clinical care from a shortcut model.
The Diagnostic Process: What Proper Testing Actually Involves
Diagnosis requires more than a single testosterone reading. The Endocrine Society and American Urological Association guidelines recommend two early-morning fasting blood draws on separate days to confirm consistently low levels.
Both total and free testosterone matter. Sex hormone-binding globulin (SHBG) can bind testosterone and reduce the amount available to the body, which makes free testosterone the more clinically meaningful measure in many men.
Assay quality matters as well. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold-standard method for accurate measurement, while older immunoassay methods can be imprecise.
A comprehensive evaluation may also include DHEA, thyroid function, cortisol, PSA, hematocrit, a lipid panel, metabolic markers, and inflammatory biomarkers. This diagnostic rigor is what distinguishes a clinically structured program from a quick online prescription, and it matters for both safety and results.
The 2025–2026 Regulatory Transformation: What Changed and Why It Matters
The TRAVERSE trial, the largest randomized controlled trial on testosterone safety ever conducted, enrolled 5,246 men aged 45 to 80. It found no significant increase in major adverse cardiovascular events (MACE) with TRT versus placebo in hypogonadal men.
In February 2025, the FDA issued class-wide labeling changes for all testosterone products, removing the black box warning related to increased cardiovascular risk. This shift was driven directly by the TRAVERSE results.
In December 2025, an FDA expert panel of urology, endocrinology, and men’s health specialists urged further label revisions. These included removing prostate cancer contraindications not supported by contemporary evidence and reconsidering testosterone’s classification as a controlled substance.
As of June 2026, HHS has proposed extending label updates to remove the “limitation of use” for age-related hypogonadism and to restrict TRT contraindication only to men with metastatic prostate cancer. This is one of the most significant regulatory shifts since 2015. For patients, it points toward expanded access and reduced stigma, though it does not eliminate the need for proper diagnosis and clinical oversight.
Delivery Methods: Understanding the Clinical Tradeoffs
Several delivery modalities exist, each with its own profile:
- Intramuscular injections (cypionate or enanthate, every 1 to 4 weeks)
- Subcutaneous injections (50 to 100 mg weekly)
- Transdermal gels (daily application)
- Oral testosterone undecanoate
- Subcutaneous pellets (every 3 to 6 months)
The pharmacokinetics differ in ways that are often overlooked. Intramuscular injections produce peak-and-trough cycles that some men notice as energy fluctuations. Lower-dose weekly subcutaneous injections tend to produce more stable levels. Pellets provide the most consistent steady-state delivery but require a minor in-office procedure. Gels offer daily flexibility but carry absorption variability and transfer risk.
Injectable formulations currently hold the largest market share at around 55% of revenue, while oral options are growing for their convenience. No single method is universally superior. The right choice is a clinical decision based on lifestyle, lab response, and provider assessment, refined through ongoing monitoring.
What to Expect: Outcomes Supported by Clinical Evidence
A 2025 narrative review found that TRT consistently improved sexual desire, erectile function, lean body mass, bone mineral density, insulin sensitivity, and vitality in men aged 50 and above with baseline testosterone below 300 ng/dL, targeting levels of 500 to 800 ng/dL.
Energy and vitality. Fatigue and low motivation are among the most commonly reported symptoms of hypogonadism and among the first to improve when levels are optimized. Effect sizes vary based on baseline and individual response.
Sleep quality. A 2017 clinical study found that one year of TRT was associated with improvements in sleep quality and overall well-being. A 2015 study found TRT reduced nocturia, improving sleep continuity.
Body composition. Evidence supports gains in lean mass, reductions in fat mass, decreased waist circumference, and improved insulin sensitivity, particularly when TRT is combined with structured lifestyle work.
Mood and cognition. Improvements in mood and cognitive performance are documented, though effect sizes are variable and most pronounced in men with confirmed deficiency rather than low-normal levels. A 2026 Frontiers in Endocrinology study found that testosterone plus lifestyle therapy improved skeletal muscle glycolysis in older hypogonadal men with obesity, reinforcing the metabolic and longevity rationale for integrated programs.
The Intersection of Hormonal and Metabolic Health
The relationship between testosterone and metabolic health runs in both directions. Low testosterone contributes to fat accumulation and insulin resistance, while obesity and metabolic dysfunction suppress testosterone production.
A study presented at ENDO 2025 found that GLP-1 receptor agonist therapy increased the percentage of men with normal testosterone from 53% to 77% over roughly 18 months. In other words, metabolic correction can restore hormonal function in some men without TRT. To understand more about how these medications work, see what is GLP-1 and how it fits into a broader metabolic care strategy.
Red Mountain may prescribe a compounded version of a GLP-1. Compounded GLP-1s contain semaglutide or tirzepatide. Compounded GLP-1s have not been approved by the FDA or reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1s have not been demonstrated to the FDA to be safe or effective for weight loss. Compounded GLP-1s manufacturing processes have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ask your provider for more information.
For men with obesity-related low testosterone, addressing metabolic health first or concurrently may amplify hormonal outcomes. This is why a comprehensive metabolic assessment, not just a testosterone panel, is the appropriate starting point. Within Red Mountain’s care architecture, the Foundation stage (metabolic correction) and the Function stage (hormone optimization) are designed to work together.
Why Lifestyle Integration Is Not Optional
A 2025 JCEM study investigated whether TRT conveys cardiometabolic benefit beyond intensive lifestyle therapy, and 2026 Frontiers research found that the combination produced superior skeletal muscle metabolic outcomes.
The lesson is consistent: TRT is a tool, not a substitute. Without addressing sleep, nutrition, physical activity, and stress, the hormonal environment that suppressed testosterone in the first place remains intact. Obesity, sedentary behavior, sleep apnea, and chronic stress are all major modifiable contributors, and a program that ignores them is clinically incomplete. Structured lifestyle support is the mechanism that turns hormonal optimization into durable improvement, which is precisely what direct-to-consumer prescription models tend to leave out.
Safety: An Honest, Nuanced Picture
The cardiovascular evidence is reassuring. TRAVERSE and three large multicenter RCTs found no significant increase in MACE versus placebo, which was the basis for the FDA’s February 2025 black box warning removal.
TRAVERSE also revealed nuances worth respecting: increased risks of non-fatal arrhythmias, venous thromboembolic events, and fractures in the testosterone group. These require ongoing monitoring.
Erythrocytosis (elevated red blood cell count) remains the most common dose-related adverse effect, requiring regular hematocrit checks. FDA-mandated ambulatory studies showed statistically significant blood pressure elevations, making blood pressure monitoring a required component of management. On prostate cancer, contemporary evidence does not support the historical blanket contraindication for men without metastatic disease.
Importantly, this safety profile applies to men with confirmed hypogonadism receiving guideline-based care, not to anti-aging or performance use in men with normal testosterone.
The Monitoring Protocol: What Ongoing Oversight Requires
Standard monitoring per Endocrine Society and AUA guidelines includes testosterone level checks timed to the delivery method, PSA screening, hematocrit assessment, blood pressure monitoring, and symptom review.
Timing matters. Levels should be checked at consistent intervals relative to the method (mid-cycle for injections, trough for pellets) to avoid misleading readings. Achieving the 500 to 800 ng/dL target is an ongoing process, not a one-time calibration. Monitoring also watches for the TRAVERSE safety signals. Far from a burden, this oversight is the feature that keeps outcomes on track and catches issues early.
Special Considerations: Men in Their 40s, Fertility, and Cardiovascular History
Men in their 40s, with a 6 to 12% prevalence of low testosterone, face a specific concern: exogenous testosterone suppresses sperm production. If fertility is a priority, alternatives such as hCG or clomiphene warrant discussion.
Men with cardiovascular history have relevant data to consider, since TRAVERSE enrolled men with established disease or high risk. The arrhythmia and thromboembolic nuances make careful monitoring especially important. Men with active or metastatic prostate cancer remain outside the candidate pool, and PSA monitoring stays standard. Men with sleep apnea should have it addressed, as untreated apnea can blunt the response to TRT. These details are precisely why individualized evaluation matters more than a generic protocol.
Hormone Optimization as Part of a Longer-Term Health Strategy
Within longevity medicine, TRT addresses several hallmarks of aging: sarcopenia, metabolic dysfunction, bone loss, and physical decline. The goal is not a number on a lab report but sustained function, including energy that supports activity, sleep that supports recovery, and body composition that supports metabolic health.
Hormone levels and metabolic conditions change over time, so the approach calls for periodic recalibration rather than a set-and-forget model. Hormone optimization works best on a metabolic foundation and is protected over time through ongoing monitoring. With only about 5% of hypogonadal men receiving treatment, the broader point is straightforward: treatable symptoms should not be filed away as “just getting older.”
Conclusion: Hormone Therapy as a Clinically Structured Program, Not a Shortcut
Hormone therapy for men is most effective and most safe when approached as a clinically structured, metabolically integrated program rather than a standalone prescription. The elements that distinguish a well-designed program are consistent: rigorous diagnosis, appropriate delivery method selection, lifestyle integration, and ongoing monitoring.
The 2025 and 2026 changes to testosterone labeling reflect a maturing evidence base. For men who recognize the symptoms described here (persistent fatigue, changing body composition, disrupted sleep, low motivation), the right next step is a proper clinical evaluation, not self-diagnosis or an online prescription. The evidence is clearer than it has ever been, and the remaining barrier is often simply starting the conversation.
Is Hormone Therapy Right for You? Starting the Conversation
A clinical consultation is the appropriate way to determine whether hormone therapy is indicated, what the diagnostic process involves, and what a structured program would look like for a specific individual.
A first consultation at Red Mountain typically involves a review of symptoms, medical history, and lifestyle factors; an explanation of the diagnostic process; and a discussion of what integrated hormone optimization looks like within the broader care framework. Red Mountain places hormone optimization within the Function stage of care, designed for men who have begun addressing their metabolic health or who want to address both at once. Men interested in learning more about how testosterone affects overall health may find additional context helpful before their first appointment.
For men seeking a structured, evidence-based approach, a consultation is the clearest next step.
